Drug Profile

NGM 936

Alternative Names: NGM-936

Latest Information Update: 11 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NGM Biopharmaceuticals
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Acute myeloid leukaemia; Multiple myeloma

Highest Development Phases

Preclinical Acute myeloid leukaemia; Multiple myeloma

Most Recent Events

09 Jan 2023 NGM 936 is available for licensing as of 09 Jan 2023. http://www.ngmbio.com
09 Jan 2023 Preclinical trials in Multiple myeloma in USA (Parenteral)
12 Dec 2022 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia released by NGM Biopharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com